Intelligent Bio Solutions Inc. filed its quarterly report on Form 10-Q for the three months ended September 30, 2026, with the SEC on November 10, 2026, reporting a net loss of $2,658,302 attributable to the company alongside a year-over-year increase in revenue.

Key Highlights

  • Revenue increased: The company reported revenue of $1,391,835 for the three months ended September 30, 2026, up from $1,111,797 in the same period of the prior year.
  • Net loss narrowed: Net loss attributable to Intelligent Bio Solutions Inc. was $2,658,302, compared to $2,983,006 in the three months ended September 30, 2025.
  • Cash position grew: Cash and cash equivalents stood at $5,929,871 as of September 30, 2026, up from $3,992,312 as of June 30, 2026.
  • Warrant exercises raised capital: Common stock issued for warrants exercised, net of issuance costs, contributed $4,418,663 to shareholders' equity during the quarter.
  • Shares outstanding: As of November 10, 2026, there were 3,316,803 shares of common stock issued and outstanding.
  • Loss per share: Net loss per share, basic and diluted, was $(0.86) for the quarter, compared to $(3.49) in the prior-year quarter.

Intelligent Bio Solutions Reports Q1 FY2027 Financials: Revenue Growth, Reduced Loss

According to the filing, Intelligent Bio Solutions Inc. (NASDAQ:INBS) generated revenue of $1,391,835 for the three months ended September 30, 2026, a rise from $1,111,797 in the comparable prior-year period. Gross profit for the quarter was reported at $758,004, up from $518,291 a year earlier. Cost of revenue, exclusive of amortization, was $633,831 compared to $593,506 in the prior-year period.

The company disclosed total operating expenses of $3,646,252 for the quarter, which included selling, general and administrative expenses of $2,579,641, development and regulatory approval expenses of $829,544, and depreciation and amortization of $237,067. The filing noted no impairment of long-lived assets in the current quarter, whereas $261,780 had been recorded in the same period of fiscal 2026. Loss from operations was reported at $2,682,747, an improvement from $3,001,187 in the prior-year quarter. Government support income of $205,501 was also recorded, the company disclosed.

On the balance sheet, total assets as of September 30, 2026 were $13,621,675, compared to $11,941,836 as of June 30, 2026. Total shareholders' equity was $7,352,528 as of September 30, 2026, up from $5,290,826 at June 30, 2026. The accumulated deficit reached $77,622,342 as of September 30, 2026. During the quarter, the company raised $265,373 net through at-the-market offerings and $4,418,663 net through warrant exercises, according to the filing. The company is classified as a non-accelerated filer and a smaller reporting company.

What Was Disclosed

Intelligent Bio Solutions Inc. filed a Form 10-Q for the fiscal quarter ended September 30, 2026, disclosing revenue of $1,391,835, a net loss attributable to the company of $2,658,302, cash of $5,929,871, and total assets of $13,621,675.